SCHEMBL8198719

SCHEMBL8198719

Clc1ccc2[nH]c(-c3ccc(C4=NCCN4)cc3)cc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.59
▸ RECQL P46063 1/20 0.59
▸ KDM4E B2RXH2 2/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ NPC1 O15118 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ MAPT P10636 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ CYP19A1 P11511 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ NISCH Q9Y2I1 2/20 0.49
▸ PRMT3 O60678 1/20 0.47
▸ EHMT2 Q96KQ7 1/20 0.47
▸ PRMT6 Q96LA8 1/20 0.47
▸ PRMT1 Q99873 1/20 0.47
▸ PRMT8 Q9NR22 1/20 0.47
▸ MAOA P21397 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL362453 0.80 PRMT1 (0.68) NISCHPRMT3EHMT2PRMT6PRMT1
Hydrochloric Acid SCHEMBL3383477 0.79 PRMT1 (0.66) NISCHPRMT3EHMT2PRMT6PRMT1
SCHEMBL7662705 0.79 KMT2A (0.79) LMNAKDM4EMEN1NPC1ALDH1A1
SCHEMBL8238119 0.79 PRMT1 (0.69) NISCHPRMT3EHMT2PRMT6PRMT1
SCHEMBL523059 0.77 LMNA (0.96) LMNARECQLNISCH
SCHEMBL8188355 0.76 LMNA (0.92) LMNARECQLNISCH
Hydrochloric Acid SCHEMBL6785326 0.75 PRMT1 (0.47) LMNARECQLNISCHPRMT3EHMT2
SCHEMBL14854511 0.75 PRMT1 (0.58) NISCHPRMT3EHMT2PRMT6PRMT1
SCHEMBL8229714 0.74 PRMT1 (0.71) NISCHPRMT3EHMT2PRMT6PRMT1
SCHEMBL13204586 0.74 PRMT1 (0.62) NISCHPRMT3EHMT2PRMT6PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2000078726-A1 IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES ELI LILLY AND COMPANY (US) 2000-12-28 — — WO disclosed
Send feedback